羟芬利定 | 546-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 羟芬利定
• 中文别名: 苄醇度冷丁
• 英文名称: 1-(2-hydroxy-2-phenyl-ethyl)-4-phenyl-piperidine-4-carboxylic acid ethyl ester
• 英文别名: 1-(β-hydroxy-phenethyl)-4-phenyl-piperidine-4-carboxylic acid ethyl ester；1-(β-Hydroxy-phenaethyl)-4-phenyl-piperidin-4-carbonsaeure-aethylester；4-Phenyl-1-(2-hydroxy-2-phenyl-ethyl)-4-ethoxycarbonyl-piperidin；Oxpheneridine；ethyl 1-(2-hydroxy-2-phenylethyl)-4-phenylpiperidine-4-carboxylate
• CAS: 546-32-7
• 化学式: C₂₂H₂₇NO₃
• 分子量: 353.461
• InChiKey: DBDXZFAMJLGFGD-UHFFFAOYSA-N

物化性质

• 熔点：
  128.5 °C(Solv: ethanol (64-17-5))
• 沸点：
  489.9±45.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  1-苄基-4-苯基-4-哌啶羧酸乙酯 在 palladium on activated charcoal 、 乙醇 作用下， 生成 羟芬利定
  参考文献：
  名称：

  The Preparation and Analgesic Activity of 4-Carbethoxy-4-phenyl-1-(2-phenylethyl)piperidine and Related Compounds

  摘要：

  DOI：

  10.1021/jo01107a028

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION
  申请人：G.L. Pharma GmbH

  公开号：EP3210596A1

  公开（公告）日：2017-08-30

  Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

  本发明公开了一种抑制滥用的药物组合物，该药物组合物包含具有酶反应官能团的药物（其中该药物具有滥用潜力）和能够与酶反应官能团发生反应的酶（药物加工酶），其中具有酶反应官能团的药物以贮存稳定、酶反应状态包含在药物组合物中，并且在没有酶活性作用于该药物的条件下。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Abuse-deterrent pharmaceutical composition
  申请人：G.L. PHARMA GMBH

  公开号：US11077196B2

  公开（公告）日：2021-08-03

  Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

  本发明公开了一种抑制滥用的药物组合物，该药物组合物包含具有酶反应官能团的药物（其中该药物具有滥用潜力）和能够与酶反应官能团发生反应的酶（药物加工酶），其中具有酶反应官能团的药物以贮存稳定、酶反应状态包含在药物组合物中，并且在没有酶活性作用于该药物的条件下。
• Ligands of the mu, kappa, and delta opioid receptors
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US11213518B2

  公开（公告）日：2022-01-04

  Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the μ opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.

  本发明公开了μ、卡帕和δ阿片受体的配体及其使用方法。特别是，本发明涉及基于对μ阿片受体构象状态的分子动力学模拟发现新的阿片受体配体，以及将所发现的阿片受体配体用作镇痛剂、止泻剂和过量逆转剂。